Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Long-Term Debt Repayments (2020)

10x Genomics (TXG) has disclosed Long-Term Debt Repayments for 1 consecutive years, with $31.3 million as the latest value for Q1 2020.

  • Quarterly Long-Term Debt Repayments changed N/A to $31.3 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $31.3 million through Dec 2020, changed N/A year-over-year, with the annual reading at $31.3 million for FY2020, N/A changed from the prior year.
  • Long-Term Debt Repayments hit $31.3 million in Q1 2020 for 10x Genomics.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $31.3 million in Q1 2020 to a low of $31.3 million in Q1 2020.